Drugs / 11C-BMS-986196
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05064436 | Dec 2021 → Dec 2023 | multiple sclerosis | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 11C-BMS-986196 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05064436 ↗ |
| Route | Intravenous | “after intravenous (IV) administration” NCT05064436 ↗ |